#China #Chengdu #Synthetic Biology #Tsingke Biotech #Quality Audit

Tsingke's Commitment to Quality in Synthetic Biology Manufacturing

In the rapidly evolving field of synthetic biology, where innovation meets essential quality standards, Beijing Tsingke Biotech Co., Ltd. is making significant strides. On October 22, 2026, the company hosted a customer quality audit at its Chengdu manufacturing facility, led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. This audit not only demonstrates Tsingke's dedication to high manufacturing standards but also reflects its ambition to refine quality management processes in the bioscience sector.

Key Focus Areas of the Audit

The quality audit scrutinized four critical components of Tsingke's operations:
1. Raw Material Traceability:
The evaluation examined how raw materials are tracked from receipt through inventory to production. This includes artifacts such as Certificates of Analysis (COAs), acceptance records, and overall end-to-end traceability across the manufacturing process.
2. Equipment Lifecycle Management:
The assessment of equipment lifecycle looked at qualification protocols, calibration, maintenance schedules, and ongoing monitoring practices. Ensuring machinery operates within the highest standards is crucial to maintaining product quality.
3. Data Integrity and Computerized Systems:
A thorough review of the data management systems validated core system access controls, data archiving procedures, and backup mechanisms. This is essential for transparency and data reliability throughout Tsingke’s processes.
4. Biological Sample Management:
The audit included a detailed look at how biological samples are managed within the facility—covering processes from receipt and identification to storage, retention, and eventual disposal.

These comprehensive assessments showcase Tsingke's proactive approach to integrating quality control systems into daily operations.

Advancing AI + Molecular Manufacturing

Tsingke operates on an innovative “AI + Molecular Manufacturing” strategy. This model emphasizes the importance of standardized workflows and robust quality controls while leveraging reliable production data to enhance operational efficiency. The company’s Gene Factory model merges molecular manufacturing with digital technologies, enabling real-time analytics and process optimization.

The insights gained from the audit reinforce the necessity of maintaining standardized processes to support digitally enabled manufacturing, which is pivotal in today’s competitive biopharmaceutical market.

Commitment to Excellence

In light of this audit, Tsingke is committed to not only advancing its manufacturing processes but also enhancing its quality management systems. By incorporating advanced digital technologies and AI applications, Tsingke is positioning itself for future growth, scalability, and long-term partnerships with its clients. This dedication to excellence serves to empower researchers and biopharmaceutical innovators worldwide with state-of-the-art biomanufacturing solutions.

About Tsingke Biotech

Founded in the heart of Beijing, Tsingke Biotech stands as a prominent player in the biotechnology industry, specializing in research and therapeutic development solutions. Their expertise encompasses molecular biology and genetics, along with services like custom DNA/RNA synthesis, gene cloning, protein expression, and viral vector packaging. Their operational facilities, certified under ISO 13485, feature Class 100,000 cleanroom environments to ensure the utmost reliability and quality in their manufacturing processes. With a strong foundation of advanced automation and a global team of experts, Tsingke accelerates innovation in drug discovery, functional genomics, and genetic engineering.

For further updates on Tsingke and its innovations, follow the company on LinkedIn.